Biomerica, Inc. BMRA shares are trading higher after the company announced it has signed two definitive agreements with Mount Sinai Medical School in NY to scale-up a laboratory version serological test for coronavirus that enables high-volume screenings in labs.
'While there are unknowns about the transfer and scale-up process, if successful the Company believes it could have commercial sales within weeks. Biomerica will file for expedited clearance with the FDA under the new EUA process for this new test format," according to the company.
Biomerica is engaged in the development, manufacturing, and marketing medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.
Biomerica shares were trading up 14.5% at $8.02 on Thursday. The stock has a 52-week high of $23.39 and a 52-week low of $2.05.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
